What is the price-to-earnings ratio of Antigenics?
The price-earnings ratio of Antigenics is currently 0.
Antigenics P/S 2025
Antigenics P/S
0
Ticker
ANTI
ISIN
US0370311013
WKN
932075
As of Jul 24, 2025, Antigenics's P/S ratio stood at 0, a 0% change from the 0 P/S ratio recorded in the previous year.
The Antigenics P/S history
Antigenics Aktienanalyse
What does Antigenics do?
Antigenics Inc, now Agenus Inc, is a biotechnology company specializing in the research and development of innovative therapies for cancer and infectious diseases. The company is headquartered in Lexington, Massachusetts. The history of Antigenics begins in the late 1980s when the founder, Garo Armen, developed a method for identifying DNA sequences that encode specific proteins. The approach was based on the isolation of lentiviral vectors from human cells, which were then used to transfer the DNA sequences to other cells. This method allowed Antigenics to identify a variety of tumor-specific antigens (TSA) that could serve as potential targets for immunotherapies. In the 1990s, Antigenics focused on developing anti-tumor vaccines based on TSA. The first product was Oncophage, a vaccine made from individual TSA peptides isolated from the patient's tumor cells. Oncophage was tested in Phase II clinical trials in patients with various forms of cancer, including melanoma, renal cell carcinoma, and glioblastoma. Although the vaccine showed significant survival benefits in some studies, it was not approved in the United States. Today, Oncophage is used in Russia and India for the treatment of kidney cancer. In the late 2000s, Antigenics expanded its portfolio to include other immune-oncology approaches such as immune checkpoint protein CTLA-4 modulators, cytotoxic antibodies against cancer cells, and small molecules for immune activation. In 2014, the company was renamed Agenus Inc to reflect its expanded business model. Today, Agenus focuses on the development of immune combination therapies that combine various approaches to activate and modulate the immune system to achieve synergistic effects. The focus is on the use of immune checkpoint inhibitors that relieve T-cell inhibition, as well as the combination of vaccines and cytotoxic antibodies. Agenus' current products include immune checkpoint inhibitor CTLA-4 Ig, which is being tested in Phase III clinical trials for melanoma and lung cancer, and the QS-21 vaccine, which elicits a strong immune response and is used as an adjuvant for other vaccines for the treatment of infectious diseases. Agenus has various divisions, including a division for veterinary immunotherapies, which specializes in the development of vaccines and treatment methods for dogs and horses with cancer. Overall, Agenus has a rich history in the research and development of immunotherapies for the treatment of cancer and infectious diseases. Although the company has experienced setbacks in the past, it remains a key player in the field of immune-oncology and is expected to develop further groundbreaking therapies. Antigenics ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Antigenics's P/S Ratio
Antigenics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Antigenics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Antigenics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Antigenics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Antigenics stock
How has the price-earnings ratio of Antigenics changed compared to last year?
The price-to-earnings ratio of Antigenics has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Antigenics high compared to other companies?
Yes, the price-to-earnings ratio of Antigenics is high compared to other companies.
How does an increase in the price-earnings ratio of Antigenics affect the company?
An increase in the price-earnings ratio of Antigenics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Antigenics affect the company?
A decrease in the price-earnings ratio of Antigenics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Antigenics?
Some factors that influence the price-earnings ratio of Antigenics are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Antigenics pay?
Over the past 12 months, Antigenics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Antigenics is expected to pay a dividend of 0 USD.
What is the dividend yield of Antigenics?
The current dividend yield of Antigenics is .
When does Antigenics pay dividends?
Antigenics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Antigenics?
Antigenics paid dividends every year for the past 0 years.
What is the dividend of Antigenics?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Antigenics located?
Antigenics is assigned to the '-' sector.
Wann musste ich die Aktien von Antigenics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Antigenics from 7/24/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/24/2025.
When did Antigenics pay the last dividend?
The last dividend was paid out on 7/24/2025.
What was the dividend of Antigenics in the year 2024?
In the year 2024, Antigenics distributed 0 USD as dividends.
In which currency does Antigenics pay out the dividend?
The dividends of Antigenics are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Antigenics
Our stock analysis for Antigenics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Antigenics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.